PRNewsWire
22 Jun 2026, 04:37 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Insilico Medicine and SK Biopharmaceuticals entered a neuroimmune disorder R&D collaboration with a total potential deal value exceeding $2.5 billion. — The high potential deal value and strategic focus on high-unmet-need CNS disorders provide a significant valuation catalyst for Insilico.
+0.60Insilico Medicine is eligible to receive up to $18 million in upfront and near-term milestone payments from the agreement. — Immediate cash inflows improve short-term liquidity and validate the commercial utility of the AI platform.
+0.30The partnership represents a record total potential deal value secured by Insilico with any Asia-Pacific (APAC) partner to date. — Demonstrates expanding market penetration and increasing institutional trust in AI-driven discovery within the APAC region.
+0.20Which stocks this story touches
Continue reading
6 related stories
Search tags
Insilico Medicine secured a record-breaking R&D collaboration deal worth up to $2.5 billion.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
5h ago
